Atara Biotherapeutics (ATRA)

• Market cap: $37.8M
• 1 day: -16.09%
• 5 days: -57.75%
• 1 month: -36.52%
• 3 months: -29.96%
• 6 months: -45.48%
• Year to date: -53.60%
• 1 year: -63.26%
• 5 years: -98.25%
• 10 years: -98.90%
• Sector: Healthcare
• Industry: Biological Products, Except Diagnostic Substances

About: Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).

Employees: 159

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

9% more repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 11

15.51% less ownership

Funds ownership: 58.11% [Q2] → 42.61% (-15.51%) [Q3]

19% less capital invested

Capital invested by funds: $24.2M [Q2] → $19.6M (-$4.53M) [Q3]

29% less funds holding

Funds holding: 48 [Q2] → 34 (-14) [Q3]

75% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 16

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $17 159% upside
• Avg. target: $21 220% upside
• High target: $25 281% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

Canaccord Genuity John Newman 52% 1-year accuracy 14 / 27 met price target	159% upside $17	Buy Maintained	17 Jan 2025
Rodman & Renshaw Tony Butler 80% 1-year accuracy 4 / 5 met price target	281% upside $25	Buy Initiated	20 Dec 2024